S

hares of Biogen (BIIB) dropped more than 3 percent Thursday after the Cambridge, Mass., biotech reported that an experimental Alzheimer’s drug it’s co-developing with a Japanese company showed disappointing results in a mid-stage clinical trial.

But the setback affects only one of a half-dozen compounds Biogen is developing to target Alzheimer’s disease, the memory-ravaging neurodegenerative disorder that is expected to affect about one in nine baby boomers and cost the nation $1 trillion by 2050.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.